⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5698810 | 0.76 | — | — | |
| SCHEMBL299778 | 0.61 | — | — | |
| SCHEMBL1000111 | 0.59 | — | — | |
| SCHEMBL37648 | 0.59 | — | — | |
| SCHEMBL1496265 | 0.54 | — | — | |
| SCHEMBL1054620 | 0.54 | — | — | |
| SCHEMBL7946672 | 0.54 | — | — | |
| SCHEMBL17847691 | 0.50 | — | — | |
| SCHEMBL831131 | 0.50 | ALDH1A1 (0.32) | — | |
| SCHEMBL14534464 | 0.50 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 675 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858360-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-08 | — | — | US | claimed |
| US-20170369498-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | US | claimed |
| EP-2686320-B1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-05-18 | — | — | EP | claimed |
| EP-2686320-A1 | TRICYCLIC GYRASE INHIBITORS | Trius Therapeutics, Inc. (US) | 2014-01-22 | — | — | EP | claimed |
| WO-2012125746-A9 | TRICYCLIC GYRASE INHIBITORS | TRIUS THERAPEUTICS INC. (US) | 2013-10-24 | — | — | WO | claimed |
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | US | claimed |
| WO-2012125746-A1 | TRICYCLIC GYRASE INHIBITORS | TRIUS THERAPEUTICS INC. (US) | 2012-09-20 | — | — | WO | claimed |
| EP-1654225-A4 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2007-11-28 | — | — | EP | claimed |
| EP-1709039-A1 | METALLIC COMPLEXES USED AS LIGHT-ABSORBENT COMPOUNDS IN THE INFORMATION LAYER OF OPTICAL DATA CARRIERS | Lanxess Deutschland GmbH (DE) | 2006-10-11 | — | — | EP | claimed |
| EP-1654225-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | Amgen, Inc. (US) | 2006-05-10 | — | — | EP | claimed |
| US-20050256161-A1 | Melanin concentrating hormone receptor antagonists | AMGEN INC. | 2005-11-17 | — | — | US | claimed |
| WO-2005068459-A1 | METALLIC COMPLEXES USED AS LIGHT-ABSORBENT COMPOUNDS IN THE INFORMATION LAYER OF OPTICAL DATA CARRIERS | LANXESS DEUTSCHLAND GMBH (DE) | 2005-07-28 | — | — | WO | claimed |
| WO-2005019240-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | AMGEN, INC. (US) | 2005-03-03 | — | — | WO | claimed |
| EP-3893872-B1 | ORGANOPHOSPHORUS-SUBSTITUTED COMPOUNDS AS C-MET INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA INC (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-12030892-B2 | CRBN modulators | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| EP-1116486-A1 | MEDICAL COMPOSITION CONTAINING NITROETHENEAMINE DERIVATIVE OR SALT THEREOF AS ACTIVE CONSTITUENT | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2001-07-18 | — | — | EP | disclosed |
| EP-1056734-A2 | SUBSTITUTED ALXOXYCARBONYL COMPOUNDS | BAYER AG (DE) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999042457-A2 | SUBSTITUTED ALXOXYCARBONYL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-08-26 | — | — | WO | disclosed |
| US-5280034-A | Bis-heterocyclic prostaglandin analogs | E. R. SQUIBB & SONS, INC. (US) | 1994-01-18 | — | — | US | disclosed |